|
| Press Releases |
|
 |
|
| Wednesday, April 9, 2025 |
|
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
| SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
|
中國抗體製藥有限公司SM17治療特應性皮炎1b期概念驗證臨床試驗取得突破性結果 |
| 中國抗體製藥有限公司（「中國抗體」或「本公司」；股份代號：3681）宣佈，其SM17針對中重度特應性皮炎（AD）的創新療法已完成1b期臨床研究，並獲得突破性頂線數據結果。 more info >> |
|
|
中国抗体制药有限公司SM17治疗特应性皮炎1b期概念验证临床试验取得突破性结果 |
| 中国抗体制药有限公司（“中国抗体”或“本公司”；股份代号：3681）宣布，其SM17针对中重度特应性皮炎（AD）的创新疗法已完成1b期临床研究，并获得突破性顶线数据结果。 more info >> |
|
| Tuesday, April 16, 2024 |
|
|
中国抗体SM17治疗特应性皮炎（AD）之临床前结果刊登于国际科学期刊《Allergy》 |
| more info >> |
|
|
中國抗體SM17治療特應性皮炎（AD）之臨床前結果刊登於國際科學期刊《Allergy》 |
| more info >> |
|
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
| SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
中国抗体SM17新药研究申请再获国家药监局批准 |
| 专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司（上市编号：3681.HK，下称“中国抗体”或“本公司”）欣然宣布，本公司所提交之治疗特应性皮炎（“AD”）的同类首创（First-in-Class）治疗产品SM17的新药研究申请（“新药研究申请”） more info >> |
|
|
中國抗體SM17新藥研究申請再獲國家藥監局批准 |
| 專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司（上市編號：3681.HK，下稱「中國抗體」或「本公司」）欣然宣佈，本公司所提交之治療特應性皮炎（「AD」）的同類首創（First-in-Class）治療產品SM17的新藥研究申請（「新藥研究申請」） more info >> |
|
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, August 14, 2023 |
|
|
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准 |
| 专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司（上市编号：3681.HK，下称“中国抗体”或“本公司”）欣然宣布，本公司所提交之治疗哮喘的同类首创(First-in-Class)治疗产品SM17的新药研究申请（“新药研究申请”）于2023年8月11日获中国国家药品监督管理局（“国家药监局”）批准。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
维珍妮25财年纯利增28.4%至1.8亿港元 末期息每股4.3港仙
Jun 26, 2025 18:36 HKT/SGT
|
|
|
On Its Centennial: The Occasion of Replacing the Kiswa of the Noble Kaaba Embodies the Kingdom of Saudi Arabia's Enduring Care for the Two Holy Mosques
Jun 26, 2025 17:57 HKT/SGT
|
|
|
World's Premier AI Conference, World AI Show - Indonesia 2025, Arrives in Jakarta to Power Southeast Asia's AI Revolution
Jun 26, 2025 12:31 HKT/SGT
|
|
|
Honda Opens "Honda Software Studio Osaka" as New Software Development Operation
Jun 26, 2025 13:30 JST
|
|
|
アリックスパートナーズ、「2025年版グローバル自動車業界見通し」を発表
Jun 26, 2025 12:30: JST
|
|
|
Honda Issues "Honda ESG Report 2025"
Jun 26, 2025 13:29 JST
|
|
|
曹操出行在港上市 成為港股最大科技出行平台
Jun 26, 2025 12:06 HKT/SGT
|
|
|
Fujitsu's Uvance Wayfinders consulting empowers customers to evolve business foundations leveraging data and AI
Jun 26, 2025 11:00 JST
|
|
|
XCF Global and Continual Renewable Ventures Announce Memorandum of Understanding to Launch New Rise Australia, a SAF and HVO Platform Powered by XCF
Jun 26, 2025 09:30 HKT/SGT
|
|
|
穩定幣條例下的隱形巨頭：百仕達的真實價值
Jun 26, 2025 09:03 HKT/SGT
|
|
|
稳定币条例下的隐形巨头：百仕达的真实价值
Jun 26, 2025 08:59 HKT/SGT
|
|
|
港股「香水第一股」穎通控股（06883）今日正式掛牌
Jun 26, 2025 07:05 HKT/SGT
|
|
|
港股“香水第一股”颖通控股（06883）今日正式挂牌
Jun 26, 2025 07:02 HKT/SGT
|
|
|
Investing News Network Strengthens Australian Presence with Appointment of Industry Veteran John Phillips
Jun 26, 2025 00:39 HKT/SGT
|
|
|
Silo Pharma Enters Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Jun 25, 2025 21:27 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
